NIAIDNews Profile Banner
NIAID News Profile
NIAID News

@NIAIDNews

Followers
68K
Following
100
Media
2K
Statuses
6K

Official X acct of National Institute of Allergy and Infectious Diseases (NIAID), part of @NIH. Engagement ≠ endorsement. Privacy policy: https://t.co/89LaCNQdAr

Bethesda, MD
Joined July 2009
Don't wanna be here? Send us removal request.
@NIAIDNews
NIAID News
8 months
#NIAID’s broad-based approach to autoimmune disease research has the potential to improve understanding and lead to treatments for many different #autoimmune diseases. Learn more: https://t.co/XtYLXJHJwn #AutoimmuneAwarenessMonth #autoimmunity #NIH #PublicHealth
7
2
8
@NIAIDNews
NIAID News
8 months
Looking for resources to support your #autoimmune disease research? Explore available research resources at https://t.co/BTW3Wj2j6b #AutoimmuneAwareness #ResearchResources #NIAID
0
2
5
@NIAIDNews
NIAID News
8 months
#NIAID supports research on #autoimmunity to improve understanding of diseases like rheumatoid arthritis, #lupus, & type 1 diabetes. This research helps inform new experimental methods of diagnosis, prevention, & treatment. Learn more: https://t.co/ZmUm5Vx5US #AutoimmuneResearch
Tweet card summary image
niaid.nih.gov
An overview of various autoimmune diseases which are the focus of NIAID-supported basic and clinical research.
0
3
6
@NIAIDNews
NIAID News
8 months
📢 NIH BioArt Source, a free science and biomedical art resource library, offers an array of high-quality illustrations, vectors, & brushes, free to use & download. See the full catalog of free science and #biomedical illustrations: https://t.co/PsdZK3HEvd #FreeResource
2
281
840
@NIAIDNews
NIAID News
8 months
12. Among people with #HIV in several African countries, a monovalent COVID-19 vaccine booster was as effective at protecting against symptomatic COVID-19 as a newer, bivalent booster:
croiconference.org
Background Prospective trials have not previously compared the efficacy of boosting with the ancestral/monovalent mRNA vaccine (WA-1) versus a bivalent ancestral plus BA.4/BA.5-targeted vaccine in...
1
0
0
@NIAIDNews
NIAID News
8 months
11. Monitoring levels of #HIV pre-exposure prophylaxis (#PrEP) drugs in the urine of pregnant & postpartum women helped them take PrEP at its prescribed frequency:
croiconference.org
Background Non-adherence to oral TDF/FTC PrEP reduces efficacy for HIV prevention, including in pregnant and postpartum women (PPW). Urine tenofovir (TFV) testing detects dosing in past 72 hours in...
1
0
0
@NIAIDNews
NIAID News
8 months
10. A novel group of therapeutic #HIV vaccines was safe & induced an immune response in people with HIV on #AntiretroviralTherapy, inducing stronger responses in younger people:
croiconference.org
Background Durable antiretroviral therapy (ART)-free remission from HIV will likely require a robust and targeted T cell response to limit viral reactivation.  Methods We report a double-blind,...
1
0
0
@NIAIDNews
NIAID News
8 months
9. Some people with HIV who acquired SARS-CoV-2 experienced structural brain changes that were not detected in a cohort before the COVID-19 pandemic, based on an exploratory analysis from an #HIV treatment study that included periodic brain MRIs:
croiconference.org
Background Healthy individuals who contract SARS-CoV-2 exhibit structural brain changes after infection. To assess whether SARS-CoV-2 is associated with unique or additive brain effects among people...
1
0
0
@NIAIDNews
NIAID News
8 months
7. An analysis from an international study of people with #HIV found that switching to an integrase strand transfer inhibitor-based #AntiretroviralTherapy regimen increased the risk of weight gain & cardiometabolic complications over the next five years:
croiconference.org
Background Integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) has been associated with disproportionate weight gain among people with HIV (PWH), primarily in treatment-n...
1
0
0
@NIAIDNews
NIAID News
8 months
6. An analysis from an international study found that higher levels of frailty were associated with an increased risk of major adverse cardiovascular events in people with #HIV:
croiconference.org
Background People with HIV (PWH) are at increased risk for atherosclerotic cardiovascular diseases (ASCVD) and accelerated aging, including frailty. REPRIEVE demonstrated a 36% reduction in the...
1
0
0
@NIAIDNews
NIAID News
8 months
5. An analysis from an international study of people with #HIV identified factors associated with benefitting from a reduced risk of major adverse cardiovascular events while taking a statin:
croiconference.org
Background REPRIEVE established that pitavastatin prevents major adverse cardiovascular events (MACE) and reduces noncalcified coronary plaque (NCP) on coronary CT angiography, in low-moderate risk...
1
0
0
@NIAIDNews
NIAID News
8 months
4. A study showed for the first time the presence of mutations on a certain part of the #HIV virus in people who were taking a common #AntiretroviralTherapy regimen & who had unsuppressed viral replication:
croiconference.org
Background Tenofovir-lamuvidine-dolutegravir (TLD) is highly effective as ART but the causes of virologic failure (VF) in individuals on TLD without integrase (IN) resistance mutations are not well...
1
0
0
@NIAIDNews
NIAID News
8 months
2. The early start of #HIV #AntiretroviralTherapy had no effect on cardiovascular disease (CVD) risk in people with HIV who were at low risk of CVD & had relatively high viral suppression before the study:
Tweet card summary image
croiconference.org
Background Cardiovascular disease (CVD) risk is higher in people with HIV (PWH) than people without HIV. However, whether this elevated risk of CVD is present in antiretroviral therapy (ART)-naïve...
1
0
0
@NIAIDNews
NIAID News
8 months
1. An analysis from an international study characterized the response to integrase strand transfer inhibitor-based #AntiretroviralTherapy after acquiring HIV while taking long-acting cabotegravir for #HIV pre-exposure prophylaxis:
croiconference.org
Background Data on antiretroviral therapy (ART) outcomes in persons who acquire HIV with long-acting cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) are limited. We evaluated ART outcomes in...
1
0
0
@NIAIDNews
NIAID News
8 months
Follow this thread for the final update about #NIAID-supported research from #CROI2025. For full text abstracts, please visit:
croiconference.org
2
1
0
@NIAIDNews
NIAID News
8 months
Trial of experimental Lassa fever #vaccine now enrolling volunteers. Learn more at https://t.co/52FdM6535w
0
4
10
@NIAIDNews
NIAID News
8 months
#ECZEMA NEWS: #TopicalSteroidWithdrawal (#TSW)—which results in dermatitis distinct from eczema—is caused by an excess of an essential compound in the body, according to a new #NIAID study, which identified possible treatments in a pilot study. https://t.co/NdAnQvwkvD
2
1
7
@NIAIDNews
NIAID News
8 months
11. A randomized controlled trial examined a mobile health service strategy combining #HIV prevention and treatment with addiction care and other services for people who inject drugs. Learn more:
Tweet card summary image
croiconference.org
Background People who inject drugs (PWID) face high morbidity and mortality from addiction and HIV. This abstract reports findings from HPTN 094 on whether 26 weeks of “one stop” integrated health...
0
0
0